You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Extracellular NAMPT is a Novel Therapeutic Target in Chorioamnionitis-Related Prematurity (ChorP)

    SBC: AQUALUNG THERAPEUTICS CORP.            Topic: NICHD

    ABSTRACT: Intrauterine infection and chorioamnionitis are common complications of pregnancy associated with significant maternal, perinatal, and long-term adverse outcomes. Adverse maternal outcomes include postpartum infections and sepsis while adverse infant outcomes include stillbirth, premature birth, neonatal sepsis, chronic lung disease and brain injury leading to cerebral palsy and other ne ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Therapeutic targeting of Nox2 and Nox4 in Duchenne Muscular Dystrophy

    SBC: Fibronox            Topic: NHLBI

    ABSTRACT: Duchenne muscular dystrophy (DMD) caused by a genetic mutation that prevents the production of dystrophin, a protein that muscles need to work properly. DMD patients exhibit progressive muscle weakness occurs in both skeletal and cardiac muscle. Cardiac fibrosis is ultimately the leading cause of their premature death. There is no cure for DMD, thus it remains an unmet medical need. Any ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Improving data capture in clinical research using a chatbot

    SBC: Dokbot, LLC            Topic: NLM

    PROJECT SUMMARY . Collecting complete and accurate outcome data directly from research participants is becoming increasingly important. Clinical researchers needs a cost-effective approach to capture high-quality patient-reported outcomes. Typically, data captured directly from participants is through self-administered questionnaires or through a human interviewer, each with their own advantages ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. The MICELI Aggregometer: a Point-of-Care Platelet Function Analyzer

    SBC: PLAKDX, LLC            Topic: NHLBI

    PROJECT SUMMARY: While platelets are vital blood cells to maintain vascular integrity and foster tissue repair, unfortunately they may become “inappropriately” activated in a wide range of disease states. To reduce this activation risk anti- thrombotic drugs are routinely prescribed to an ever increasing variety of patients, in fact being leading agents prescribed by physicians today. While th ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Analysis of new compounds to treat familial hypercholesterolemia

    SBC: GRUTHAN BIOSCIENCE LLC            Topic: NHLBI

    PROJECT SUMMARY The long-term goal of the current proposal is to generate a new class of small molecules to treat familial hypercholesterolemia. Familial hypercholesterolemia (FH) patients suffer from excessively high levels of Low Density Lipoprotein Cholesterol (LDL-C), which if left untreated results in death from severe cardiovascular disease. FH is caused primarily by mutations in the LDL rec ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. DEVELOPMENT OF NOVEL AMINOGLYCOSIDE POLYMERS AND NANOPARTICLES FOR NUCLEIC ACID DELIVERY IN CHRONIC WOUNDS

    SBC: Synergyan, LLC            Topic: NCATS

    PROJECT SUMMARYThe purpose of this Phase I STTR project is to develop targeted nanoparticles for the combinatorial delivery of nucleic acids and small molecule drugs as therapeutics. We have previously developed a library of novel aminoglycoside-derived polymer nanoparticles capable of simultaneously delivering nucleic acids and small molecule drugs or imaging agents into mammalian cells. The effi ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Development of surfactant protein A-derived peptidomimetics for the treatment of asthma

    SBC: RaeSedo, LLC            Topic: NHLBI

    Current treatments for asthma, while reducing exacerbations in a subset of patients by focusing on airway inflammation, do not eliminate them. There is no current innate immune modulator for the treatment of asthma. Asthma exacerbations are a significant cause of morbidity and mortality in asthma as they can lead to airway injury, lung function decline and death. The cause of an exacerbation is of ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis

    SBC: AQUALUNG THERAPEUTICS CORP.            Topic: NHLBI

    ABSTRACT The development of radiation-induced lung injury (RILI) is a potentially fatal toxicity in cancer patients undergoing thoracic radiotherapy or in individuals exposed to ionizing radiation (IR) from a nuclear incident. The pathobiology of radiation pneumonitis and radiation-induced lung fibrosis (RILF) is complex but includes the deleterious effects of unchecked inflammation (reactive oxyg ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Therapeutic Antibody Targeting of Extracellular NAMPT in Ventilator-Induced Lung Injury (VILI)

    SBC: AQUALUNG THERAPEUTICS CORP.            Topic: NHLBI

    Mortality rates in intensive care units (ICUs) are unacceptably high and are directly related to the duration of mechanical ventilation that is required to support patients with respiratory failure. For example, acute respiratory distress syndrome (ARDS) is a vexing acute inflammatory lung disease requiring mechanical ventilatory support as the result of severe hypoxemia and respiratory failure. T ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Delivery of chemically modified PNA oligomers

    SBC: NUBAD, LLC            Topic: NIAID

    PROJECT SUMMARYRNA is a validated target for drug design, both as therapeutic and as a target. Targeting specific RNA, such as rRNA which are involved in proliferation and survival of bacteria is a promising approach. We are developing fast and low cost methods to screen sequence-specific small molecules for novel anti-ribosomal activities. We will construct sequence-specific chemically modified r ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government